Maternal and fetal outcomes associated with CFTR modulator use during pregnancy: a scoping review. (PubMed, Eur Respir Rev) - Sep 24, 2026 - "We analysed clinical studies, registry data and related literature published between 2003 and 2025 to assess reported differences in lung function, birth weight, pregnancy and neonatal complications, mode of delivery and screening biomarkers among pregnancies in women with CF treated with ivacaftor, lumacaftor/ivacaftor, tezacaftor/ivacaftor or elexacaftor/tezacaftor/ivacaftor, compared with pregnancies not exposed to CFTRm.Available evidence suggests that elexacaftor/tezacaftor/ivacaftor may improve maternal health through better lung function and nutritional status, while inadvertent fetal drug exposure has not been clearly associated with serious adverse outcomes. There is also insufficient evidence to establish the safety of infant exposure or prolonged maternal CFTRm use during lactation. This review highlights the need for future studies evaluating dose optimisation, long-term follow-up of infants and children, and integration of registry data to better define..."
Journal • Review • Cystic Fibrosis • Genetic Disorders • Immunology • Pulmonary Disease • Respiratory Diseases • CFTR
|
|
Aleksandar Dobric; André Schultz; Daniel L Rolnik; Danni Li; Elena K Schneider-Futschik; Ellen Menkhorst; Imogen Felton; Jamie Duckers; Jane Davies; Jennifer L Taylor-Cousar; Luke Richardson; Peter G Middleton; Peter Wark; Rasa Ruseckaite; Siân Bentley; Zhengzheng Liu; Zihanjiao Wang
|